Effexor (Venlafaxine) Tapering Guide
Venlafaxine is an SNRI antidepressant. Most people take a prolonged-release or extended-release form once a day; it is sold as Efexor XL in the UK and Effexor XR in the US. This guide and medication taper calculator help you plan how to wean off Effexor with your prescriber — they do not tell you what dose to take or in what order.
Dosage
In the UK, venlafaxine is available as prolonged-release capsules and tablets taken once a day, as standard-release tablets taken more than once a day, and as a licensed oral solution (37.5 mg or 75 mg in each 5 mL). In the US, extended-release capsules commonly come in 37.5 mg, 75 mg and 150 mg, and standard-release tablets are also available.
Prolonged-release capsules are not designed to be divided, and the lowest common strength is a long way from nothing. If a plan you and your prescriber agree involves doses below what a capsule allows, liquid is usually how that is done.
Venlafaxine taper schedule
Choose a common starting dose to preview an example hyperbolic schedule you can take to your prescriber — free, no email required. This example has 42 steps and takes about 164 weeks in total. It is a planning tool, not a dose instruction.
Starting dose
- Selected start
- 150 mg/day · 1× daily
- Taper speed
- Slow
- Region (formulations)
- US
- Modelled occupancy at start
- ~78.7%
Tablet/liquid products used for dosing tips — not your location. Example uses US formulary; change region in the custom builder.
Swipe sideways to see every column.
| Step | Daily (mg) | How to take it | Per dose × 1/day | Hold (weeks) |
|---|---|---|---|---|
| 0 | 150 | Your current dose — hold steady before step 1. | 150 mg × 1 | — |
| 1 | 100 | Take 4 × 25 mg IR tablet tablets (100 mg active ingredient total). | 100 mg × 1 | 4 |
| 2 | 75 | Take 3 × 25 mg IR tablet tablets (75 mg active ingredient total). | 75 mg × 1 | 4 |
| 3 | 62.5 | Take 2 whole 25 mg tablets + half of a scored 25 mg tablet (12.5 mg) ≈ 62.5 mg active ingredient. | 62.5 mg × 1 | 4 |
| 4 | 50 | Take 2 × 25 mg IR tablet tablets (50 mg active ingredient total). | 50 mg × 1 | 4 |
| 5 | 44.82 | GPSee liquid / compounding note below | 44.82 mg × 1 | 4 |
| 6 | 37.5 | Take 1 whole 25 mg tablet + half of a scored 25 mg tablet (12.5 mg) ≈ 37.5 mg active ingredient. | 37.5 mg × 1 | 4 |
| 7 | 34.14 | GPSee liquid / compounding note below | 34.14 mg × 1 | 4 |
| 8 | 25 | Take 1 × 25 mg IR tablet tablet (25 mg active ingredient total). | 25 mg × 1 | 4 |
| 9 | 23.1 | GPSee liquid / compounding note below | 23.1 mg × 1 | 4 |
| 10 | 21.4 | GPSee liquid / compounding note below | 21.4 mg × 1 | 4 |
| 11 | 19.85 | GPSee liquid / compounding note below | 19.85 mg × 1 | 4 |
| 12 | 18.4 | GPSee liquid / compounding note below | 18.4 mg × 1 | 4 |
| 13 | 17.1 | GPSee liquid / compounding note below | 17.1 mg × 1 | 4 |
| 14 | 15.9 | GPSee liquid / compounding note below | 15.9 mg × 1 | 4 |
| 15 | 14.8 | GPSee liquid / compounding note below | 14.8 mg × 1 | 4 |
| 16 | 13.8 | GPSee liquid / compounding note below | 13.8 mg × 1 | 4 |
| 17 | 12.85 | GPSee liquid / compounding note below | 12.85 mg × 1 | 4 |
| 18 | 11.95 | GPSee liquid / compounding note below | 11.95 mg × 1 | 4 |
| 19 | 11.15 | GPSee liquid / compounding note below | 11.15 mg × 1 | 4 |
| 20 | 10.4 | GPSee liquid / compounding note below | 10.4 mg × 1 | 4 |
| 21 | 9.7 | GPSee liquid / compounding note below | 9.7 mg × 1 | 4 |
| 22 | 9.05 | GPSee liquid / compounding note below | 9.05 mg × 1 | 4 |
| 23 | 8.4 | GPSee liquid / compounding note below | 8.4 mg × 1 | 4 |
| 24 | 7.8 | GPSee liquid / compounding note below | 7.8 mg × 1 | 4 |
| 25 | 7.25 | GPSee liquid / compounding note below | 7.25 mg × 1 | 4 |
| 26 | 6.7 | GPSee liquid / compounding note below | 6.7 mg × 1 | 4 |
| 27 | 6.2 | GPSee liquid / compounding note below | 6.2 mg × 1 | 4 |
| 28 | 5.75 | GPSee liquid / compounding note below | 5.75 mg × 1 | 4 |
| 29 | 5.3 | GPSee liquid / compounding note below | 5.3 mg × 1 | 4 |
| 30 | 4.85 | GPSee liquid / compounding note below | 4.85 mg × 1 | 4 |
| 31 | 4.45 | GPSee liquid / compounding note below | 4.45 mg × 1 | 4 |
| 32 | 4.05 | GPSee liquid / compounding note below | 4.05 mg × 1 | 4 |
| 33 | 3.7 | GPSee liquid / compounding note below | 3.7 mg × 1 | 4 |
| 34 | 3.35 | GPSee liquid / compounding note below | 3.35 mg × 1 | 4 |
| 35 | 3 | GPSee liquid / compounding note below | 3 mg × 1 | 4 |
| 36 | 2.7 | GPSee liquid / compounding note below | 2.7 mg × 1 | 4 |
| 37 | 2.4 | GPSee liquid / compounding note below | 2.4 mg × 1 | 4 |
| 38 | 2.1 | GPSee liquid / compounding note below | 2.1 mg × 1 | 4 |
| 39 | 1.8 | GPSee liquid / compounding note below | 1.8 mg × 1 | 4 |
| 40 | 1.55 | GPSee liquid / compounding note below | 1.55 mg × 1 | 4 |
| 41 | 1.5 | GPSee liquid / compounding note below | 1.5 mg × 1 | 4 |
Rows highlighted: larger occupancy drop than target — consider smaller steps or longer holds. If symptoms are intolerable, return to the previous dose and talk to your prescriber.
Steps that cannot be made from whole or half licensed tablets point to the liquid / compounding note below — ask your prescriber before changing how you take your dose.
Want a copy to keep?
The full venlafaxine schedule is already shown below. Enter your email to also receive a PDF and HTML copy you can save or share with your prescriber — optional, and we never gate the schedule behind it.
It's not a substitute for medical advice. This calculator can help you visualise a tapering schedule but before making any changes to your medication plan it's necessary to consult a medical professional. Ask a psychiatrist — available after you request your protocol.
Dose vs occupancy
This example is spread across 42 gradual steps. The curve below shows why the last few milligrams matter most: at low doses, small dose changes produce large drops in serotonin-transporter occupancy.
What this shows: the non-linear relationship between dose and serotonin transporter (SERT) occupancy. The curve is flat at high doses — most transporters are already blocked, so a dose cut has little biological impact — and much steeper at low doses, where even a 1–2 mg reduction causes a disproportionately large drop in occupancy. Your taper steps are spaced along this curve so each step removes a similar amount of occupancy.
Hill curve of modelled receptor occupancy versus dose. Current dose near 150.0 milligrams per day.
Modelled Hill-curve occupancy — illustrative only. PET-derived parameters vary by study; your prescriber may use different clinical targets. Small mg changes near zero can still produce large occupancy shifts.
Want a full taper protocol?
This page shows a quick schedule for this drug. For the guided path — pre-taper risk quiz, formulation-aware steps, and email delivery — continue in the builder.
How to Taper Off Effexor (Venlafaxine) Safely
How to taper off Effexor (venlafaxine) safely starts with its speed: this SNRI leaves the body faster than any other commonly used antidepressant, so missed doses and sharp reductions are felt quickly. The calculator on this page drafts an example hyperbolic schedule to take to your prescriber — it is not a dose instruction.
Most people take a prolonged-release or extended-release form once a day. It is sold as Efexor XL in the UK and Effexor XR in the US. Standard-release preparations also exist and are taken more than once a day. Which form you are on matters more with venlafaxine than with most antidepressants.
About this guide
This is general information about venlafaxine for people taking it, thinking about starting or stopping. It is not personal medical advice, and it does not tell you what dose to take or how to change one. Those decisions belong with the prescriber who knows your history.
If anything here differs from what your own doctor or pharmacist has told you, go with them.
How long people usually take it
Venlafaxine is not usually a short course. The UK product information states that people should be treated for a sufficient period, usually several months or longer, and that for depression treatment should continue for at least six months following recovery. NICE gives similar advice for antidepressants generally, with regular review, and longer for people who have had several episodes.
This matters if you are thinking about stopping, because stopping early carries a real risk. In a UK trial in general practice, among people who had been well enough that stopping seemed reasonable, 56% of those who stopped became unwell again within a year, compared with 39% of those who continued. That is not an argument for staying on antidepressants indefinitely, and many people come off them successfully and stay well. It is an argument for the timing being a decision you make deliberately with your prescriber, rather than one you make on the day you run out.
What people commonly notice while taking it
The effects listed as very common in the UK product information are nausea, dry mouth, headache, and sweating including night sweats. Common ones include difficulty sleeping, reduced appetite, dizziness, sedation, tremor, a faster heartbeat, constipation, diarrhoea, vomiting, rash, tiredness and weakness. Sexual side effects, including difficulty with ejaculation and reduced sex drive, are also frequently reported.
A few other things about venlafaxine are worth knowing, and they are the reasons your prescriber may want to see you rather than just renew a prescription. Venlafaxine can raise blood pressure, and the effect is related to the dose, so it matters more at higher doses. Having it checked before starting and periodically afterwards is standard practice. There can be modest increases in pulse rate. Disturbances of the heart's electrical rhythm have also been reported, although these cases are mostly in overdose. Tell your prescriber if you have a heart problem or a family history of sudden cardiac death.
In the manufacturer's data, clinically relevant rises in cholesterol were recorded in about one in twenty people taking venlafaxine long term, which is why it may be checked from time to time. Venlafaxine can also affect judgement, thinking and coordination, so be cautious about driving or using machinery, especially early on or after a change. The product information advises against alcohol. There is a small increase in bleeding risk, a small risk of low blood sodium which is more likely in older people, and it can widen the pupil, which matters for people at risk of a type of glaucoma where eye pressure rises suddenly.
Thinking about stopping
There are many different reasons for people to think about stopping. This can be that they have been well for a long time, the side effects have come to outweigh the benefit, they are planning a pregnancy, or circumstances have changed.
What helps is having the conversation before the plan rather than after it. Some questions that are worth taking to the appointment:
- how long you have been taking it, and how long it has been since you last felt unwell
- whether anything in the next few months makes this a difficult time to start
- what happened if you have tried before, and what you would do differently
- how the two of you will tell withdrawal symptoms from the original problem returning
- who you contact, and how quickly, if it becomes difficult
One thing is worth being clear about: venlafaxine should not be stopped abruptly. NICE advises against stopping antidepressants suddenly except in rare and serious circumstances, such as a severe reaction to the medicine.
What coming off Effexor actually feels like, week by week
Venlafaxine leaves the body faster than any other commonly used antidepressant. Its half-life, the time for the level in the blood to halve, is about 5 hours for the immediate-release preparations, and approximately 11 hours for extended-release preparations.
The practical consequence is that the level in your blood rises and falls within a single day. Many people find that being even a few hours late with a dose is noticeable, and that missing one entirely is unmistakable. This is sometimes called missed-dose withdrawal, and it is not imagination.
What people describe after a reduction that was larger than they could comfortably absorb is intense and often constant electric-shock sensations known as brain zaps, dizziness, nausea, sweating, agitation, and a distinctive difficulty holding attention on anything.
Venlafaxine is consistently reported as among the hardest antidepressants to stop, alongside paroxetine, in comparisons across the whole class. If you have read that somewhere and found it discouraging, it is not an exaggeration. It is also not a reason to conclude that stopping is not possible. It is a reason to go slowly, keep the timing steady, and have the plan agreed rather than improvised.
How common is this? The research does not give a clean answer, and it is worth being straight about that. A large review published in 2024 found that about a third of people had at least one symptom after stopping an antidepressant, but also that about one in six had symptoms after stopping a dummy tablet, leaving roughly one in six or seven that could be attributed to the medicine itself. A reanalysis published in 2025, which looked only at the studies that asked people systematically rather than waiting for them to volunteer symptoms, arrived at around half.
Almost all of that research involves people who had taken antidepressants for a few months. Very little of it describes what happens after several years, which is the situation many people reading this are actually in.
Those figures are for antidepressants as a group. Venlafaxine sits at the difficult end of the range rather than in the middle of it.
Withdrawal or relapse — how to tell them apart
Withdrawal symptoms tend to begin within hours to a day of a change, and to ease just as quickly if the previous dose is restored. If your symptoms track your dose changes almost in real time, that pattern points to withdrawal.
A return of depression or anxiety tends to build over weeks, resembles how your original illness felt rather than a physical upset, and does not lift within a day or two if the dose goes back up.
That distinction is useful, but it is not perfect and it should not be used as a test you apply alone. NICE's guidance on withdrawal makes the point directly that withdrawal symptoms can be delayed, can be prolonged, and can affect mental health as well as physical health. If you cannot tell which you are dealing with, that is a normal position to be in and a good reason to speak to your prescriber.
Why the last part is often the hardest
This catches people out, and it is worth understanding, because it is the most common reason a reduction that had been going well stops going well.
The relationship between the dose and the effect at the nerve cell is not a straight line. At higher doses the effect is close to its ceiling, so removing some milligrams changes relatively little. At low doses, removing the same number of milligrams makes a much bigger difference.
In practical terms, a reduction that you barely noticed near the top can feel like a much larger change near the bottom, even though the arithmetic looks identical. This is why NICE recommends reductions that are proportionate to the dose you are currently taking, so that the steps become smaller as the dose comes down, and it is why the final stretch often takes longer than everything before it.
It is a feature of how the medicine works. It is not a sign that something has gone wrong, and it is not a sign that you are doing it badly.
The practical part of this is that prolonged-release capsules are not designed to be divided, and the lowest common strength is a long way from nothing. So at exactly the point where the steps need to get smaller, the available forms stop being able to make them smaller. That is the wall people describe hitting, and it is a problem about available formulations.
Effexor taper schedules by starting dose (225, 150, 75, 37.5 mg)
How to taper off Effexor is shaped by two facts: the drug clears quickly, and the common prolonged-release strengths stop being able to make small steps just when occupancy demands them. The table above is an example planning schedule to take to your prescriber, not a sequence to run at home.
At higher starting doses, early occupancy is close to its ceiling, so milligram changes can look larger than they feel. The harder stretch is usually the lower end — including from the lowest common XR strength — because finishing often needs a different form: standard-release tablets, a licensed liquid, or another approach your prescriber discusses with you.
Two other approaches are sometimes used, and neither is something to attempt on your own. One is changing between forms so the dose can be adjusted more finely. The other is switching to a longer-acting antidepressant and reducing that instead. That second option sits outside the product licence; the evidence is clinical experience rather than trial data, and it does not suit everyone, because venlafaxine acts on two chemical messengers and the medicine usually chosen for this acts on only one.
If it gets worse: pausing and reinstatement
If a reduction is harder than you expected, or if being a few hours late with a dose feels unmistakable, speak to your prescriber. With a medicine that clears this quickly, improvising the next step is a poor substitute for an agreed plan.
This is educational information. Do not change your dose without your prescriber's input.
The forms venlafaxine comes in
In the UK, venlafaxine is available as prolonged-release capsules and tablets taken once a day, as standard-release tablets taken more than once a day, and as a licensed oral solution containing either 37.5 mg or 75 mg in each 5 mL. The oral solution is taken in divided doses through the day rather than once daily.
In the US, the extended-release capsules come in 37.5 mg, 75 mg and 150 mg, and standard-release tablets are also available.
If a plan you and your prescriber agree involves doses below what a capsule or tablet allows, liquid is usually how that is done. Whether that applies to you, and which product, is a question for them. Asking about the liquid is reasonable, particularly if you are approaching the lowest capsule strength and wondering what happens next.
A note on what your leaflet says
The patient information leaflet in the box often says that when stopping, the dose should be reduced over a period of at least one to two weeks. NICE's guidance on withdrawal describes a slower, stepwise reduction that gets gentler as the dose falls, and says the process can take several months or more.
If your leaflet and your prescriber appear to disagree, this is usually why. Neither is making a mistake. The leaflet states a minimum; the guideline describes what many people actually need.
When to get help quickly
Contact your prescriber promptly if:
- your mood drops significantly, or you feel worse than you did before you started
- you have thoughts of harming yourself or ending your life. If you are in immediate danger, call emergency services — 911 in the US, or your local emergency number
- symptoms after a dose change are getting worse rather than settling, or you cannot manage them
- you become confused or unsteady, or feel physically unwell in a way that is new
- you develop agitation with shivering, twitching, a racing heart or a fever
- you become pregnant, or are planning to
Stopping venlafaxine suddenly is not the answer to any of the above. Speak to someone first. Crisis lines for your region are listed at the bottom of this page.
The bottom line
Effexor is among the harder antidepressants to stop, but people do stop it. The ones who describe it going well almost always describe a slow plan with the right formulation available, rather than a display of determination. Take the planning table to your prescriber, keep the timing steady, and ask what form comes after the lowest capsule.
Milligram scale guidance (advanced — prescriber/pharmacist approval required)
When a dose is below what you can split from a licensed tablet, some people weigh crushed tablet powder. This is not exact chemistry — it is a last resort. Liquid or compounded formulations are safer when available.
- Resolution: at least 0.001 g (1 mg) — not a kitchen scale.
- Include a calibration weight and use a draft shield if possible.
- Weigh on a stable surface; tare your container first.
- Crushed tablet weight ≠ exact active ingredient — drug may not be evenly distributed; prefer liquid or compounded specials when available.
- Never split enteric-coated (EC) or extended-release (XR) products — discuss with your pharmacist.
Example searches (confirm specs before buying):
Key facts about hyperbolic antidepressant tapering
The calculator algorithm is based on peer-reviewed research and has been reviewed by our medical advisors to ensure the accuracy of the tapering model.
72%
discontinued their antidepressant using hyperbolic tapering strips in a real-world study
71% of the same people had previously tried to stop at least once and been unsuccessful; the study did not record which method those earlier attempts used. Figures come from tapering-strip research and may not generalise to every taper.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
56 days
median taper length in that tapering-strip study — not a target; many people taper over 6–12 months or longer
This median reflects tapering-strip use in one study. Your timeline depends on how long you have taken the medication, your withdrawal symptoms, and previous attempts — slower is often safer.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
10%
serotonin transporter occupancy per tapering step
This linear reduction prevents withdrawal. Slower, more gradual tapering over several months has shown greater success in reducing withdrawal symptoms than short tapers.
Claro — tapering companion
A protocol isn’t enough — you need support.
Tapering can take months, sometimes years. Claro helps you track each step, log symptoms, and spot when a reduction was too fast — with psychiatrist-reviewed guidance. Join early access while we launch the app.
Related taper guides
Other medications with similar pharmacology or a higher population withdrawal-risk profile. Each guide links to a pre-filled hyperbolic schedule for that drug.
Frequently asked questions about venlafaxine
Common questions about how to taper off venlafaxine, hyperbolic schedules, and withdrawal — written for people who want to come off antidepressants safely with their prescriber.
Why does being a few hours late with a dose feel so bad?
Is venlafaxine really the hardest antidepressant to come off?
My prescriber has not mentioned the liquid. Should I ask?
Can I stop venlafaxine suddenly?
Why does my blood pressure keep getting checked?
Is venlafaxine addictive?
Can I drink alcohol?
I feel fine. Doesn't that mean I can stop?
What is an antidepressant tapering calculator?
Why use a tapering calculator?
How does an antidepressant taper calculator work?
What is hyperbolic tapering and why is it recommended?
What is the safest way to taper off antidepressants?
How slowly should antidepressants be reduced?
What are common antidepressant withdrawal symptoms?
What is the difference between antidepressant withdrawal and relapse?
Is it dangerous to stop antidepressants cold turkey?
Why are the last antidepressant dose reductions often the hardest?
Which antidepressants are hardest to taper off?
Need a different dose or speed?
Use the guided builder to enter your current dose, region, and taper preset — then email a draft you can review with your prescriber.
Request custom protocol →Clinical references
- [1]Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry 2019.doi:10.1016/S2215-0366(19)30032-XProposes hyperbolic dose reduction based on receptor-occupancy curves; the methodological basis of every modern taper calculator.
- [2]Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines. Wiley 2024.doi:10.1002/9781394291052Per-drug operational manual for hyperbolic tapering across SSRIs, SNRIs, benzodiazepines, gabapentinoids, and antipsychotics.
- [3]Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors 2019.doi:10.1016/j.addbeh.2018.08.027Systematic review: 56% of people who discontinue antidepressants experience withdrawal effects; 46% rate them as severe.
- [4]Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024.doi:10.1016/S2215-0366(24)00133-0Meta-analysis of 79 studies (≈21,000 patients): pooled incidence of discontinuation symptoms ~31%; severe symptoms ~2.8%.
- [5]Groot PC, van Os J. Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321103932772% of patients successfully discontinued antidepressants after switching to the hyperbolic model; 71% had previously failed to come off without tapering strips.
- [6]Groot PC, van Os J. Antidepressant tapering strips to help people come off medication: real-world outcomes. Therapeutic Advances in Psychopharmacology 2023.doi:10.1177/20451253231171518Of 1,194 patients using hyperbolic taper strips after previous failed attempts, ~71% successfully discontinued their antidepressant.
- [7]Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321991274Describes the "windows and waves" pattern of withdrawal recovery and supports patient-led pacing.
- [8]Hengartner MP et al. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320967183Descriptive analysis of 69 protracted withdrawal cases: median duration 79 weeks; 47% report suicidality during withdrawal.
- [9]Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics 2020.doi:10.1159/000506868Taxonomy distinguishing new withdrawal symptoms, rebound, and persistent post-withdrawal disorder; the standard framework for withdrawal vs. relapse.
- [10]Kalfas M et al. Incidence and Nature of Antidepressant Discontinuation Symptoms. JAMA Psychiatry 2025.doi:10.1001/jamapsychiatry.2025.1362Recent meta-analysis: dizziness was the most common discontinuation symptom in the first 2 weeks after stopping antidepressants, followed by nausea, vertigo, and nervousness.
- [11]Gabriel M, Sharma V. Antidepressant discontinuation syndrome. Canadian Medical Association Journal 2017.doi:10.1503/cmaj.160991Clinical review of antidepressant discontinuation syndrome: onset within days of dose reduction, typical symptom course, and management.
- [12]Papp A, Onton J. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. The Primary Care Companion for CNS Disorders 2018.doi:10.4088/pcc.18m02311Characterises "brain zaps" — brief electric-shock sensations — as a common antidepressant discontinuation symptom.
- [13]Wang J, Cosci F. Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review. Therapeutic Advances in Psychopharmacology 2025.doi:10.1177/20451253251404780Systematic review of acute and persistent antidepressant withdrawal syndromes; reinforces reducing only when stable and under supervision.
- [14]Horowitz M, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances 2022.doi:10.1192/bja.2021.62Frames how clinicians can distinguish antidepressant withdrawal from relapse of the underlying condition.
- [15]Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants — a systematic review. Molecular Psychiatry 2021.doi:10.1038/s41380-021-01285-wSystematic review of dose–SERT-occupancy relationships across antidepressants; confirms the hyperbolic curve underlying proportional tapering.
- [16]Reeve R, Turner JR. Pharmacodynamic models: parameterizing the Hill equation, Michaelis-Menten, the logistic curve, and relationships among these models. Journal of Biopharmaceutical Statistics 2013.doi:10.1080/10543406.2012.756496Explains how the Hill equation, Michaelis-Menten, and logistic models relate — the mathematical basis for the occupancy curve used here.
- [17]Preskorn SH. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. Journal of Psychiatric Practice 2012.LinkShows how SERT occupancy explains the non-linear dose–response curves of SSRIs.
- [18]Cohrs D, Shapiro B. The relationship between SERT occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering SRI antidepressants. SSRN (preprint) 2026.doi:10.2139/ssrn.6176553Argues the SERT-occupancy to serotonin relationship is itself hyperbolic, reinforcing proportional (hyperbolic) tapering.
- [19]Moncrieff J et al. Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. Psychological Medicine 2025.doi:10.1017/S0033291725100652Reappraisal of recent withdrawal-incidence evidence; relevant to how withdrawal rates are interpreted.
- [20]Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology 2015.doi:10.1177/2045125315612334Practical review of how to manage antidepressant discontinuation symptoms, including tapering and reinstatement.
- [21]Groot PC, van Os J. Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320954609Long-term follow-up (1–5 years) of patients who discontinued antidepressants using hyperbolic taper strips.
- [22]Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. L'Encéphale 1999.LinkHalf-life data for SSRIs — explains why short-half-life drugs (paroxetine, venlafaxine) provoke faster withdrawal.
- [23]Mayo Clinic. Antidepressant withdrawal: Is there such a thing?. Mayo Clinic — Expert Answers 2024.LinkPatient-facing explainer on antidepressant discontinuation symptoms and gradual tapering.
- [24]NHS Scotland — Right Decision Service. Antidepressants — quality prescribing: difficulty withdrawing from an SSRI/SNRI. NHS Scotland 2024.LinkNHS Scotland guidance on recognising and managing difficulty withdrawing from SSRIs/SNRIs.
- [25]The Carlat Psychiatry Report. Clinical pearls for hyperbolic tapering of psychiatric medications in older adults. The Carlat Report 2024.LinkPractical clinical pearls for applying hyperbolic tapering, including in older adults.
- [26]Royal College of Psychiatrists. Stopping antidepressants — information for patients and carers. Royal College of Psychiatrists 2024.LinkRCPsych patient-facing guidance on coming off antidepressants safely.
- [27]Takano A et al. Serotonin transporter occupancy by venlafaxine in vivo: a [11C]DASB PET study. Psychopharmacology 2006.doi:10.1007/s00213-006-0438-8PET SERT-occupancy curve for venlafaxine — anchors the SNRI hyperbolic curve.
- [28]National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. NICE 2022.LinkUK national guideline endorsing proportional (hyperbolic) tapering and the use of liquid formulations to enable small final doses.
- [29]National Institute for Health and Care Excellence (NICE). Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. NICE guideline [NG215]. NICE 2022.LinkUK national guideline on withdrawal: symptoms can be delayed or prolonged, and reductions should get gentler as the dose falls.
- [30]Lewis G et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine 2021.doi:10.1056/NEJMoa2106356Among people well enough that stopping seemed reasonable, 56% who stopped became unwell again within a year versus 39% who continued.
- [31]Royal College of Psychiatrists. Stopping antidepressants — position statement (CR225). Royal College of Psychiatrists 2020.LinkRCPsych acknowledges withdrawal can be severe and long-lasting; recommends slow, individualised tapers.
- [32]NHG et al. Multidisciplinary document: Discontinuation of SSRIs and SNRIs (2018; revised 2023). Multidisciplinary Document (Netherlands) 2018.LinkFirst national guideline to explicitly endorse hyperbolic tapering and the use of taper strips (compounded by Regenboog Apotheek).
- [33]Medicines and Healthcare products Regulatory Agency (MHRA). Summary of Product Characteristics — SSRI and SNRI products (UK). electronic Medicines Compendium (emc) 2023.LinkAuthoritative UK formulary data (tablet strengths, oral solutions) used to validate the UK region in the calculator.
- [34]U.S. Food and Drug Administration. Prescribing information (Structured Product Labeling) for SSRI/SNRI products. FDA / DailyMed 2024.LinkAuthoritative US formulary data (tablet strengths, oral solutions/concentrates) used to validate the US region in the calculator.
- [35]Health Canada. Health Canada — Drug Product Database. Health Canada 2024.LinkAuthoritative Canadian formulary data used to validate the Canada region in the calculator.
- [36]Therapeutic Goods Administration (TGA). Therapeutic Goods Administration — Australian Register of Therapeutic Goods (ARTG). TGA / ARTG 2024.LinkAuthoritative Australian formulary data used to validate the Australia region in the calculator.
- [37]College ter Beoordeling van Geneesmiddelen (CBG-MEB). CBG-MEB — Medicines Information Bank (Netherlands). CBG-MEB 2024.LinkAuthoritative Dutch formulary data; cross-checked with Regenboog Apotheek taper-strip availability.
- [38]Regenboog Apotheek, Cinetto. Taperingstrip.com — Regenboog Apotheek. Patient resource (NL) 2024.LinkPioneer of standardised taper strips referenced in the Dutch national guideline.
If you are in crisis or having thoughts of suicide, do not wait for an email response. Find a crisis helpline near you immediately →